Search Here

Swiss pharmaceutical giant Roche has announced a massive $50 billion investment into the United States over the next five years, aiming to boost biotechnology and medicine manufacturing while creating 12,000 new jobs across four key states.

The investment, detailed in a statement released Tuesday, will be spread across California, Indiana, Massachusetts, and Pennsylvania.

Roche plans to expand its research and development facilities, build new manufacturing plants, and strengthen its diagnostics capabilities in the US.

"Today's announced investments underscore our longstanding commitment to research, development and manufacturing in the US," said Roche CEO Thomas Schinecker.

The company currently employs around 25,000 people in the US and operates 15 research centers and 13 manufacturing sites nationwide. This expansion will raise that footprint to 24 sites across eight states.

Of the 12,000 jobs being created, 1,000 will be directly at Roche, while the remaining 11,000 will support the new manufacturing capabilities being developed, AP News said.

As part of the expansion, Roche will construct a new 900,000-square-foot facility for next-generation weight-loss drugs.

It also plans to open a gene therapy center in Pennsylvania and a continuous glucose monitoring plant in Indiana. Upgrades are planned for sites in Kentucky, Oregon, New Jersey, and California.

Roche to Boost US Manufacturing, Citing Long-Term Commitment

While the $50 billion figure includes some ongoing projects, a portion of it marks new commitments announced this week.

"We have conducted a thorough analysis of potential scenarios over the last weeks and are well prepared to navigate them," said Roche spokesperson Rebekka Schnell.

She added that these investments were discussed with the Swiss government and align with current US-Swiss relations.

This development comes in the wake of efforts by US President Donald Trump to encourage increased foreign investment in the country.

His recent tariffs on goods from countries including Switzerland sparked concern among international companies.

While the company did not reference tariffs in its recent announcement, Roche stated that its expanded manufacturing operations in the United States will lead to a shift in its trade balance—resulting in the export of more medicines from the US than it imports.

This move places Roche among several global companies increasing their US footprint.

According to Investopedia, Apple recently announced a $500 billion investment, and Taiwan Semiconductor plans to invest $100 billion in US manufacturing.

With nearly $74 billion in worldwide sales last year, and about a third of that coming from the US, Roche's expansion signals a long-term commitment to American biotech and pharmaceutical innovation.